Restless leg syndrome, also called as Willis-Ekbom disease is an uncomfortable and unpleasant sensation that causes an inhibition movement in legs and it can occur at any age. The cause of RLS is not known, but researchers suspect that genes play roles in the occurrence of RLS. However, certain causes that can worsen RLS are chronic diseases such as kidney failure, peripheral neuropathy, Parkinson’s disease and iron deficiency and some of the medications that can cause RLS are anti-nausea drugs, anti-depressants, anti-psychotic drugs and anti-histamines for cold and flu symptoms. The complications that arise from RLS to the patients include daytime sleepiness which affect concentration, mood, job performance and personal relationships.
RESTLESS LEG SYNDROME THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2018)
As per the National Institute of Neurological Disorders and Stroke (NINDS), the strong need or urge to move the legs that is associated with uncomfortable, unpleasant, and abnormal conditions is the one of the diagnosing conditions for RLS. The symptoms of RLS mostly arise in late evenings, which become severe during resting positions such as, lying on bed or sitting. People having RLS describe the feeling as itching, pulling, aching, throbbing, or creeping. These symptoms are less likely to occur in upper limbs, and rarely in head and chest.
Iron supplements and other medications may be helpful for managing temporary pain caused by the RLS. Positive clinical trial results and technological advancements are the factors driving the growth of the pipeline.
The RLS therapeutics pipeline comprises of eight therapeutic candidates in different stages of development.
Some of the key players developing drugs for the treatment of restless leg syndrome include Hisamitsu Pharmaceutical Co., Inc., Merz Pharma GmbH & Co KgaA, AXIM Biotechnologies Inc., and Alexza Pharmaceuticals Inc.